Inovio's first approved drug wins FDA nod; stock jumps in after-hours trade
The FDA has cleared Inovio's therapy for recurrent respiratory papillomatosis, its first approved product. Shares rose sharply in extended trading, according to Reuters.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
The US Food and Drug Administration has cleared a treatment from Inovio Pharmaceuticals for a rare breathing-tract condition, the agency said on Friday. It is the company's first approved product, Reuters reported.
The therapy, INO-3107, will be marketed as Voceryq and offers a new option for patients with recurrent respiratory papillomatosis. The disease causes growths in the airways and often requires repeated surgeries. Inovio shares climbed 215% in extended trading.
why it matters
For the broader market this matters mainly for one company, but the sharp move in the stock shows how strongly investors react to regulatory decisions on small biotech firms that had no approved products before.
tags
instruments
sources
- US FDA approves Inovio's treatment for rare throat disease; shares surge — Reuters, 30 October 2026 at 20:44 UTC
- US FDA approves Inovio's treatment for rare throat disease — Reuters, 30 October 2026 at 20:40 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗